Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, September 2011, Pages: 67

Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global alopecia market. The report identifies the key trends shaping and driving the global alopecia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global alopecia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated the global alopecia therapeutics market to be valued at $2,014.9m in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 4.8% for the next seven years to reach $2,804.4m by 2017. The market grew at a CAGR of 8.4% during the historic period (2005-2010). Propecia (finasteride) and Rogaine (minoxidil) are the only prescribed drugs for the treatment of alopecia. The patent expiry of Propecia in 2013 will impact the alopecia therapeutic market in the forecast period. However, Avodart (5a-reductase inhibitor) from GlaxoSmithKline which is an analogue to Propecia is in Phase III trials, and the drug is expected to launch by 2016. The major breakthrough in the Japan alopecia therapeutics market in the historical period was the approval of Propecia in 2006. The increasing patient population and expected launch of new drugs during the forecast period will drive the market growth.

Scope

The report provides information on the key drivers and challenges of the alopecia market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) alopecia market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as androgen receptor antagonist, 5-alphareductase inhibitor, fatty acid derivative, immunosuppressant, potassium channel opener and prostaglandin agonist.
- Analysis of the current and future competition in the seven key countries alopecia market. Key market players covered are GlaxoSmithKline, Johnson & Johnson, Allergan, Cosmo Pharmaceuticals and R-Tech Ueno.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the alopecia market.
- Analysis of key recent licensing and partnership agreements in alopecia market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global alopecia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global alopecia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global alopecia market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Alopecia Therapeutics Market - Introduction
2.1 Overview
2.1.1 Types of Alopecia
2.2 Epidemiology
2.3 Etiology
2.4 Clinical Presentation/Symptoms
2.5 Prognosis
2.6 Diagnosis
2.6.1 Clinical Examination
2.6.2 Pathological test
2.7 Pathophysiology
2.8 Treatment
2.8.1 Androgenetic alopecia
2.8.2 Alopecia areata
2.9 Pipeline Report Guidance
3 AlopeciaTherapeutics - Market Characterization
3.1 Alopecia Therapeutics Market Size (2005-2010) – Global
3.2 Alopecia Therapeutics Market Forecast (2010-2017) – Global
3.3 Alopecia Therapeutics Market Size (2005-2010) – The US
3.4 Alopecia Therapeutics Market Forecast (2010-2017) – The US
3.5 Alopecia Therapeutics Market Size (2005-2010) – France
3.6 Alopecia Therapeutics Market Forecast (2010-2017) – France
3.7 Alopecia Therapeutics Market Size (2005-2010) – Germany
3.8 Alopecia Therapeutics Market Forecast (2010-2017) – Germany
3.9 Alopecia Therapeutics Market Size (2005-2010) – Italy
3.10 Alopecia Therapeutics Market Forecast (2010-2017) – Italy
3.11 Alopecia Therapeutics Market Size (2005-2010) – Spain
3.12 Alopecia Therapeutics Market Forecast (2010-2017) – Spain
3.13 Alopecia Therapeutics Market Size (2005-2010) – The UK
3.14 Alopecia Therapeutics Market Forecast (2010-2017) – The UK
3.15 Alopecia Therapeutics Market Size (2005-2010) – Japan
3.16 Alopecia Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the Alopecia Therapeutics Market
3.17.1 Drivers for the Alopecia Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Alopecia Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Product in the Alopecia Therapeutics Market
4.3.1 Propecia (finasteride)
4.3.2 Rogaine (minoxidil)
4.3.3 Kenalog-10 (Triamcinolone acetonide)
4.4 Key Takeaway
5 Alopecia Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Alopecia Therapeutics – Pipeline Analysis by Phase of Development
5.3.1 Alopecia Therapeutics – Phase III Clinical Pipeline
5.3.2 Alopecia Therapeutics – Phase II Clinical Pipeline
5.3.3 Alopecia Therapeutics – Phase I Pipeline
5.3.4 Alopecia Therapeutics – Discovery and Preclinical Pipeline
5.4 Alopecia Therapeutics – Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Alopecia Therapeutics – Most Promising Drugs under Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 Avodart (dutasteride)
5.8 Key Takeaway
6 Alopecia Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 & Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Sponsors
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials
7 Alopecia Therapeutics Market - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Alopecia Market - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Johnson & Johnson
8.2.2 GlaxoSmithKline
8.2.3 Merck & Co.
8.2.4 Allergan Inc.
8.2.5 Cosmo Pharmaceuticals
8.2.6 R-Tech Ueno
8.3 Key Takeaway
9 Alopecia Therapeutics - Licensing and Partnership Deals
10 Alopecia Market Therapeutics - Appendix
10.1 Market Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Bibliography

1.1 List of Tables
Table 1: Alopecia Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 2: Alopecia Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 3: Alopecia Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 4: Alopecia Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 5: Alopecia Therapeutics Market, France, Revenue ($m), 2005–2010
Table 6: Alopecia Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 7: Alopecia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 8: Alopecia Therapeutics Market, Germany , Forecasts ($m), 2010–2017
Table 9: Alopecia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 10: Alopecia Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 11: Alopecia Therapeutics, Spain, Revenue ($m), 2005–2010
Table 12: Alopecia Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 13: Alopecia Therapeutics, The UK, Revenue ($m), 2005–2010
Table 14: Alopecia Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 15: Alopecia Therapeutics, Japan, Revenue ($m), 2005–2010
Table 16: Alopecia Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 17: Alopecia Therapeutics Market, Phase III Pipeline, 2011
Table 18: Alopecia Therapeutics Market, Phase II Pipeline, 2011
Table 19: Alopecia Therapeutics Market, Phase I Pipeline, 2011
Table 20: Alopecia Therapeutics Market, Discovery and Preclinical Pipeline, 2011
Table 21: Alopecia Therapeutics Market, Global, Most Promising Drugs Under Clinical Development, 2011
Table 22: Alopecia Therapeutics, Global, Clinical Trials, 2011
Table 23: Alopecia Therapeutics, Global, Clinical Trials by Phase, 2011
Table 24: Alopecia Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 25: Alopecia Therapeutics, Global, Prominent Sponsors, 2011
Table 26: Alopecia Therapeutics, Global, Top Ten Companies by Phase, 2011
Table 27: Johnson and Johnson, Alopecia Marketed Products, 2011
Table 28: GlaxoSmithKline, Alopecia Pipeline Products, 2011
Table 29: Novartis AG, Alopecia Marketed Products, 2011
Table 30: Alopecia Therapeutics, Global, Deals, 2010

1.2 List of Figures
Figure 1: Norwood-Hamilton Scale of Male Pattern Baldness
Figure 2: Ludwig Scale of Female Pattern Baldness
Figure 3: Androgenetic alopecia (Males), Treatment Protocol
Figure 4: Androgenetic alopecia (Females), Treatment Protocol
Figure 5: Alopecia Areata, Treatment Protocol
Figure 6: Alopecia Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 7: Alopecia Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 8: Alopecia Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 9: Alopecia Therapeutics Market, The US, Forecasts ($m), 2010–2017
Figure 10: Alopecia Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 11: Alopecia Therapeutics Market, France, Forecasts ($m), 2010–2017
Figure 12: Alopecia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 13: Alopecia Therapeutics Market, Germany , Forecasts ($m), 2010–2017
Figure 14: Alopecia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 15: Alopecia Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Figure 16: Alopecia Therapeutics, Spain, Revenue ($m), 2005–2010
Figure 17: Alopecia Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 18: Alopecia Therapeutics, The UK, Revenue ($m), 2005–2010
Figure 19: Alopecia Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Figure 20: Alopecia Therapeutics, Japan, Revenue ($m), 2005–2010
Figure 21: Alopecia Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 22: Opportunity and Unmet Need in the Alopecia Therapeutics Market
Figure 23: Strategic Competitor Assessment of the Marketed Products in Alopecia, 2011
Figure 24: Alopecia Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2011
Figure 25: Alopecia Therapeutics Market – Clinical Pipeline by Phase of Development (%), 2011
Figure 26: Technology Trends Analytics Framework, 2011
Figure 27: Technology Trends Analytics Frame Work – Description, 2011
Figure 28: Alopecia Therapeutics, Global, Clinical Trials by Country, 2011
Figure 29: Alopecia Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 30: Alopecia Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 31: Alopecia Therapeutics, Global, Overall Sponsors (%), 2011
Figure 32: Alopecia Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 33: Alopecia Therapeutics, Global, Top Ten Companies by Phase, 2011
Figure 34: Alopecia Therapeutics Market, Drivers and Restraints, 2011
Figure 35: Implications for Future Market Competition in the Alopecia Therapeutics Market, 2011
Figure 36: Alopecia Therapeutics Market, Clinical Pipeline by Company, 2011
Figure 37: Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Alopecia Therapeutics market. The report identifies the key trends shaping and driving the global Alopecia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Alopecia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Alopecia Therapeutics Market is forecast to Show High Growth until 2017

GlobalData has estimated the global alopecia therapeutics market to be valued at $2,014.9m in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 4.8% for the next seven years to reach $2,804.4m by 2017. The market grew at a CAGR of 8.4% during the historic period (2005-2010). Propecia (finasteride) and Rogaine (minoxidil) are the only prescribed drugs for the treatment of alopecia. The patent expiry of Propecia in 2013 will impact the alopecia therapeutic market in the forecast period. However, Avodart (5a-reductase inhibitor) from GlaxoSmithKline which is an analogue to Propecia is in Phase III trials, and the drug is expected to launch by 2016. The major breakthrough in the Japan alopecia therapeutics market in the historical period was the approval of Propecia in 2006. The increasing patient population and expected launch of new drugs during the forecast period will drive the market growth.

Alopecia Therapeutics, Global, Revenue and Market Forecast ($m), 2005–2017

Source: GlobalData, Chantal Bolduc, MD, FRCP(C) Alopecia Areata from Medscape, American academy of dermatology, M. P. Birch, “Female pattern hair loss” Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK, American hair Loss Association, GlobalData Epidemiology-based Market Forecasting Model.

The Alopecia Therapeutics Market Has High Unmet Needs to be Addressed

GlobalData analyzed the current competition in the alopecia therapeutics market and found it to be weak. Currently, Propecia and Minoxidil are the only prescribed drugs for the treatment of alopecia. These drugs target reduction of hair loss. However, due to severe adverse effects like erectile dysfunction, decreased libido, increase in heart rate and blood pressure usage of these drugs is declining and the unmet need in the market remains high. Avodart is in Phase III trials in the US and after approval it will be able to capture market share of Propecia as it is more efficacious with diverse mechanism of action. There is a huge set of patients waiting for newer therapies to treat alopecia, as well as the development of safe and efficacious drugs for the treatment of alopecia.

Johnson & Johnson
GlaxoSmithKline
Merck & Co.
Allergan Inc.
Cosmo Pharmaceuticals
R-Tech Ueno

Customers who bought this item also bought

• An Atlas of Hair Pathology with Clinical Correlations. Edition No. 2
• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Cord Blood Stem Cells – A Global Market Overview
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• Anesthesia Disposables - Global Strategic Business Report
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures